📰 Amgen News
Page 88 - Amgen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Amgen. Real-time updates on events, politics, business and more.
April 5, 2024
Former Horizon Therapeutics CCO Geoff Curtis launches consultancy. From PR Week
April 5, 2024
The availability of post-grant proceedings at the Patent Trial and Appeal Board (PTAB) has changed the face of patent litigation. This periodic digest is designed to keep you up-to-date...
April 4, 2024
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and Zura Bio (NASDAQ:ZURA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership. Insider & Institutional Ownership 82.8% of TScan […]
April 4, 2024
Householder Group Estate & Retirement Specialist LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,615 shares of the medical research company’s stock after selling 55 shares during […]
April 4, 2024
JUPITER, Fla. & DURHAM - Ligand Pharmaceuticals today announced the launch of Pelthos Therapeutics , a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to...
April 4, 2024
The average time it takes for evidence to change clinical practice is 17 years.1 Amgen is aiming to close this gap between evidence generated from trials to routine practice with implementation...
April 4, 2024
A fractured affirmance of a district court decision to dismiss an infringement action under 35 U.S.C. § 271(e)(1) was the occasion for the Federal Circuit to illustrate the continued...
April 4, 2024
Virginia lawmakers and community advocates are urging Gov. Glenn Youngkin to sign a bill into law creating a state prescription drug affordability board in an effort to lower medication prices.
April 4, 2024
Braun Stacey Associates Inc. purchased a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 45,465 shares of the medical research company’s stock, valued at approximately $13,095,000. Other institutional investors have also recently added to […]